Ductal carcinoma is a type of breast cancer that starts in the milk ducts of the breast. Accounting for approximately 80% of all breast cancer diagnoses, it begins in the milk ducts of the breast and has the potential to spread to other parts of the body if not detected and treated early. As treatment research and advancements continue to evolve, it is important to understand the latest advances in ductal cancer
Causes of ductal carcinoma:
Scientists don’t yet fully understand the exact cause of ductal cancer, but research suggests certain factors increase a woman’s risk of developing the disease. Lifestyle, environment and genes inherited from parents may all be involved.
Factors that increase your risk of ductal carcinoma in situ include:
· Increasing age
· Personal history of benign breast diseases, such as atypical hyperplasia, etc.
· Family history of breast cancer
· Never been pregnant
· Having your first child after the age of 30
· Menarche before age 12
· Menopause after age 55
· The presence of genetic mutations that increase the risk of breast cancer, such as mutations in the breast cancer genes BRCA1 and BRCA2
symptom
Ductal carcinoma in situ usually does not cause any signs or symptoms. However, ductal carcinoma in situ can sometimes cause the following signs:
1. Breast lumps
2. Bloody nipple discharge
3. Ductal carcinoma in situ can usually be found on mammography and appears as small calcification clusters of irregular shape and size.
Treatment methods for ductal carcinoma:
1. The latest treatment for ductal cancer-targeted therapy. Including hormonal therapy, HER2-targeted therapy and immunotherapy, have shown efficacy in specific subtypes of IDC. These treatments are designed to disrupt the growth and spread of cancer cells while minimizing damage to healthy cells, thereby improving patient outcomes and quality of life.
2. Immunotherapy. Research into the role of the tumor microenvironment and immune system in IDC has led to the emergence of immunotherapy as a promising therapeutic avenue. Immunotherapy offers new frontiers in the fight against aggressive ductal cancer by harnessing the body’s immune system to identify and destroy cancer cells
3. Radiotherapy. Radiation therapy uses high-energy beams, such as X-rays or protons, to kill abnormal cells. Radiation therapy after lumpectomy may reduce the chance that DCIS will return or develop into invasive cancer
4. Hormone treatment. Hormone therapy is a treatment that blocks hormones from reaching cancer cells and is only effective in cancers that grow in response to hormones (hormone receptor-positive breast cancer)
5. Clinical trials. It also plays a vital role in promoting the understanding and treatment of IDC. These trials evaluate the safety and effectiveness of new drugs, treatment combinations, and treatments, ultimately forming the standard of care for patients with breast cancer. Participation in clinical trials not only provides patients with access to cutting-edge treatments, but also contributes to the collective knowledge that advances the field of oncology
6. Breast-conserving surgery and oncology plastic surgery technology. This technology revolutionizes the treatment of IDC. These techniques focus on achieving optimal oncologic outcomes while preserving the natural appearance of the breast, thereby addressing the patient’s physical and emotional well-being
It is important for individuals diagnosed with ductal cancer to proactively seek the latest information and treatment options. Having open and informed discussions with healthcare providers, seeking second opinions, and staying informed about ongoing research are important steps in navigating the complexities of IDC.
In conclusion, the situation in ductal carcinoma is constantly evolving, driven by continued research and advancements in treatment modalities. A comprehensive understanding of the latest research and treatment options is critical for healthcare providers, researchers, and patients alike. By staying informed and embracing the latest developments, we can work to improve outcomes and quality of life for patients with invasive ductal carcinoma.
show less